C

China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062

Watchlist Manager
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
Watchlist
Price: 21.98 CNY 2.47%
Market Cap: 22.6B CNY
Have any thoughts about
China Resources Double-Crane Pharmaceutical Co Ltd?
Write Note

Wall Street
Price Targets

Price Targets Summary
China Resources Double-Crane Pharmaceutical Co Ltd

Wall Street analysts forecast China Resources Double-Crane Pharmaceutical Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for China Resources Double-Crane Pharmaceutical Co Ltd is 26.32 CNY with a low forecast of 25.25 CNY and a high forecast of 27.72 CNY.

Lowest
Price Target
25.25 CNY
15% Upside
Average
Price Target
26.32 CNY
20% Upside
Highest
Price Target
27.72 CNY
26% Upside
China Resources Double-Crane Pharmaceutical Co Ltd Competitors:
Price Targets
EAPI
Euroapi SAS
4% Downside
300765
CSPC Innovation Pharmaceutical Co Ltd
46% Upside
002422
Sichuan Kelun Pharmaceutical Co Ltd
28% Upside
HYL
Hyloris Pharmaceuticals SA
187% Upside
AXSM
Axsome Therapeutics Inc
27% Upside
SOLARA
Solara Active Pharma Sciences Ltd
42% Downside
214370
Caregen Co Ltd
24% Downside
AVDL
Avadel Pharmaceuticals PLC
91% Upside

Revenue
Forecast

Revenue Estimate
China Resources Double-Crane Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for China Resources Double-Crane Pharmaceutical Co Ltd's revenue is 9%. The projected CAGR for the next 3 years is 8%.

9%
Past Growth
8%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
China Resources Double-Crane Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for China Resources Double-Crane Pharmaceutical Co Ltd's operating income is 10%. The projected CAGR for the next 3 years is 15%.

10%
Past Growth
15%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
China Resources Double-Crane Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for China Resources Double-Crane Pharmaceutical Co Ltd's net income is 9%. The projected CAGR for the next 3 years is 16%.

9%
Past Growth
16%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is China Resources Double-Crane Pharmaceutical Co Ltd's stock price target?
Price Target
26.32 CNY

According to Wall Street analysts, the average 1-year price target for China Resources Double-Crane Pharmaceutical Co Ltd is 26.32 CNY with a low forecast of 25.25 CNY and a high forecast of 27.72 CNY.

What is China Resources Double-Crane Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
8%

For the last 8 years the compound annual growth rate for China Resources Double-Crane Pharmaceutical Co Ltd's revenue is 9%. The projected CAGR for the next 3 years is 8%.

What is China Resources Double-Crane Pharmaceutical Co Ltd's Operating Income forecast?
Projected CAGR
15%

For the last 8 years the compound annual growth rate for China Resources Double-Crane Pharmaceutical Co Ltd's operating income is 10%. The projected CAGR for the next 3 years is 15%.

What is China Resources Double-Crane Pharmaceutical Co Ltd's Net Income forecast?
Projected CAGR
16%

For the last 8 years the compound annual growth rate for China Resources Double-Crane Pharmaceutical Co Ltd's net income is 9%. The projected CAGR for the next 3 years is 16%.

Back to Top